Pre-clinical evaluation of a novel antibody drug conjugate (ADC) LM-317 targeting NaPi2b

被引：0
|
作者：
Huang, Wentao
Liu, Zhifang
Li, Yifan
Pan, Heng
Qin, Xia
Fei, Da
Li, Runsheng
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5907
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5907
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine
    Hartley, John A.
    Flynn, Michael J.
    Bingham, John P.
    Corbett, Simon
    Reinert, Halla
    Tiberghien, Arnaud
    Masterson, Luke A.
    Antonow, Dyeison
    Adams, Lauren
    Chowdhury, Sajidah
    Williams, David G.
    Mao, Shenlan
    Harper, Jay
    Havenith, Carin E. G.
    Zammarchi, Francesca
    Chivers, Simon
    van Berkel, Patrick H.
    Howard, Philip W.
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [22] Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
    Hamilton, E. P.
    Barve, M. A.
    Tolcher, A. W.
    Buscema, J.
    Papadopoulos, K. P.
    Zarwan, C.
    Anderson, C. K.
    Doroshow, D.
    Wang, D.
    Huebner, D.
    Jansen, V. M.
    Jarlenski, D.
    Mosher, R.
    Kaufman, J.
    Moore, K. N.
    Richardson, D. L.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S627 - S628
  • [23] A novel pegylated biparatopic antibody-drug conjugate (pb-adc) targeting cancers with low HER2+ expression
    Liu, Shumin
    Yin, Shuqiang
    Lyu, Weidong
    Lei, Yang
    Zhuo, Qiudong
    Wu, Zibin
    Tan, Shuangyu
    Zheng, Liling
    Wen, Yu
    Wu, David
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [24] LCB97, an antibody drug conjugate (ADC) targeting a novel tumor antigen for the treatment of multiple solid tumors
    Jeong, Yeojin
    Spohn, Gunther
    Mehli, Flavio
    Chung, Chul-Woong
    Park, Changsik
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [25] Rebmab200, a Humanized Monoclonal Antibody Targeting the Sodium Phosphate Transporter NaPi2b Displays Strong Immune Mediated Cytotoxicity against Cancer: A Novel Reagent for Targeted Antibody Therapy of Cancer
    dos Santos, Mariana Lopes
    Yeda, Fernanda Perez
    Tsuruta, Lilian Rumi
    Horta, Bruno Brasil
    Pimenta, Alecio A., Jr.
    Degaki, Theri Leica
    Soares, Ibere C.
    Tuma, Maria Carolina
    Okamoto, Oswaldo Keith
    Alves, Venancio A. F.
    Old, Lloyd J.
    Ritter, Gerd
    Moro, Ana Maria
    [J]. PLOS ONE, 2013, 8 (07):
  • [26] Pre-clinical evaluation of novel electrospun patches for intra-oral drug delivery
    Hadley, L.
    Santocildes-Romero, M. E.
    Thornhill, M. H.
    Hansen, J.
    Colley, H. E.
    Hatton, P. V.
    Murdoch, C.
    [J]. ORAL DISEASES, 2016, 22 : 10 - 10
  • [27] SCR-A002, a novel FGFR2b-targeting antibody-drug-conjugate for solid tumors
    Fu, Yayuan
    Ge, Yuanjie
    Shao, Xiaohui
    Deng, Qi
    Xia, Chunlei
    Tang, Renhong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Pre-Clinical Evaluation of a Novel Domain Antibody Targeting CD154 in a Non-Human Primate Transplant Model.
    Wakwe, W.
    Breeden, C.
    Leopardi, F.
    Farris, A.
    Song, M.
    Strobert, E.
    Jenkins, J.
    Price, K.
    Nadler, S.
    Larsen, C.
    Adams, A.
    [J]. TRANSPLANTATION, 2014, 98 : 680 - 681
  • [29] Pre-Clinical Evaluation of a Novel Domain Antibody Targeting CD154 in a Non-Human Primate Transplant Model.
    Wakwe, W.
    Breeden, C.
    Leopardi, F.
    Farris, A.
    Song, M.
    Strobert, E.
    Jenkins, J.
    Price, K.
    Nadler, S.
    Larsen, C.
    Adams, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 680 - 681
  • [30] MBRC-101: a novel antibody-drug conjugate (ADC) targeting the tyrosine kinase receptor EphA5
    Staquicini, Fernanda I.
    Tang, Fenny H.
    de Oliveira, Vanessa
    Staquicini, Daniela I.
    Wu, Yongjian
    Barnhart, Kirstin F.
    Parsons, J. Kellogg
    Arap, Wadih
    Chen, Isan
    Pasqualini, Renata
    [J]. CANCER RESEARCH, 2024, 84 (06)
12345